Colloid determination of fibrin network permeability

Gelder, James M. van; Nair, C H; Dhall, D.P.

doi:10.1097/00001721-199611000-00002

Cited by 13 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An article evaluated the performance of APC associated with albumin [32] which could represent a possible improvement in its framework, modulating the fibrin network ultrastructure and permeability. Also, the material produced in this study showed to have higher biocompatibility, and possibly more durable with a greater thickness and resistance [32,33]. However, the levels of released cytokines and growth factors were similar to those found for PRF; also, its degradation period is compatible with PRF extending to almost 10 days [1,7].…”

Section: Discussionsupporting

confidence: 54%

Tensile strength assay comparing the resistance between two different autologous platelet concentrates (leucocyte-platelet rich fibrin versus advanced-platelet rich fibrin): a pilot study

et al. 2021

View full text Add to dashboard Cite

Background Since the leucocyte-platelet rich fibrin (L-PRF) was published in 2001, many studies have been developed, analyzing its properties, and also verifying new possibilities to improve it. Thereby, it emerges the advanced-platelet rich fibrin (A-PRF) with a protocol that optimizes the properties obtained by the L-PRF. Nonetheless, there is a gap in the literature to landmark the evolutive process concerning the mechanical properties in specific the resistance to tensile strength which consequently may influence the time for membrane degradation. Thus, this study had the goal to compare the resistance to the traction of membranes produced with the original L-PRF and A-PRF protocols, being the first to this direct comparison. Findings The harvest of blood from a healthy single person, with no history of anticoagulant usage. We performed the protocols described in the literature, within a total of 13 membranes produced for each protocol (n = 26). Afterward, the membranes were prepared and submitted to a traction test assessing the maximal and the average traction achieved for each membrane. The data were analyzed statistically using the unpaired t test. Regarding average traction, A-PRF obtained a value of 0.0288 N mm−2 and L-PRF 0.0192 N mm−2 (p < 0.05 using unpaired t test). For maximal traction, A-PRF obtained 0.0752 N mm−2 and L-PRF 0.0425 N mm−2 (p < 0.05 using unpaired t test). Conclusion With this study, it was possible to conclude that indeed A-PRF has a significative higher maximal traction score and higher average traction compared to L-PRF, indicating that it had a higher resistance when two opposing forces are applied.

show abstract

Section: Discussionsupporting

confidence: 54%

Tensile strength assay comparing the resistance between two different autologous platelet concentrates (leucocyte-platelet rich fibrin versus advanced-platelet rich fibrin): a pilot study

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The size of the pores in FTA may be important for immobilization and slow delivery of materials. An assay for fibrin network permeability (30) was developed recently and may be useful in the evaluation of such indication.…”

Section: Properties and Biological Etfectmentioning

confidence: 99%

Fibrin Tissue Adhesives

Martinowitz

Spotnitz

1997

Thromb Haemost

View full text Add to dashboard Cite

Fibrin tissue adhesive" (FTA) is the name given to products, originally made from plasma proteins, that mimic the last step of the physiological coagulation cascade to form fibrin clot. The idea of enhancing hemostasis at the site of injury by local application of FTA versions dates back to the beginning of the century (l). In Europe, commercial FTAs products have been used extensively for almost 20 years for a variety of indications including hemostasis, sealing, adhesives ("gluing"), and slow release delivery system for materials such as antibiotics or growth factors. However, prospective series documating safety and efficacy for most of the indications for which FTA are used have been lacking. A few recent experimental and clinical trials suggest that in spite of the extensive clinical experience over the years , there may be no clinically important benefit of using FIA in some indications (2-5) while in others even harmful effect is suggested (6,7). The composition of IIIA, concentration of ingredients, addition in some preparates of bovine aprotinin and F. XItr are also based on in vitro data and animal experiments but not on clinical research and no standards exist for the formulation or evaluation of these products. Most users in Europe are considering FTA to be a generic name and are not aware of their large variations. Studies performed with different forms of FTA may have different outcomes (8,9) and may not be applicable to all formulations of FIA. In the US the FDA has still not aproved commercial FTA due to the lack of data on safety and efficacy. Another obstacle for approval is the "combination product regulations" that require proof for the role of each of the added components (as bovine aprotinin) to the claimed effect. (Natural proteins that are co-purify with fibrinogen do not require such proof). Insteadan extensive use of non commercial FTA was developed in the US based on blood bank products. Heterologous cryoprecipitate is used in9OVo of cases, (10) but also autologous cryoprecipitate, fresh frozen plasma or platelet rich plasma (11-13) which are combined with commercial bovine thrombin (10) to produce FTA. These combinations have much lower margin of safety as compared to commercial FTAs, which avoid the use bovine thrombin and undergo viral inactivation.

show abstract

“…Albumin addition in biomaterials slowed the degradation in vitro [ 31 ]. What’s more, it was reported that the combination of albumin and fibrin can help modulating the biomaterial’s ultrastructure and fiber thickness [ 32 ]. Heat treatment can modify the secondary structure of albumin, favoring an improvement of its resorption properties and stability [ 33 ].…”

Section: Discussionmentioning

confidence: 99%

Exploration of proper heating protocol for injectable horizontal platelet-rich fibrin gel

et al. 2022

View full text Add to dashboard Cite

Purpose Platelet-rich fibrin (PRF) has been proposed as promising biomaterials with the advantages of host accumulation of platelets and leukocytes with entrapment of growth factors and fibrin scaffold. However, limitations including fast resorption rate (~ 2 weeks) restricts its clinical application. Recent studies have demonstrated heating treatment can prolong PRF degradation. Current published articles used the method of 75 °C for 10 min to obtain longer degradation, while few studies investigated the most suitable temperature for heating horizontal PRF. Our present study was to discover and confirm the optimum temperature for heat treatment before obtaining H-PRF gels by investigating their structure, mechanical properties, and bioactivity of the H-PRF gels after heating treatment. Methods In the present study, 2-mL upper layer of horizontal PRF was collected and heated at 45 °C, 60 °C, 75 °C, and 90 °C to heat 2-mL upper layer of horizontal PRF for 10 min before mixing with the 2-mL lower layer horizontal PRF. The weight, solidification time and the degradation properties were subsequently recorded. Scanning electron microscopy (SEM) and rheologic tests were carried out to investigate the microstructure and rheologic properties of each H-PRF gel. The biological activity of each H-PRF gel was also evaluated using live/dead staining. Results H-PRF gel prepared at 75 °C for 10 min had the fast solidification period (over a tenfold increase than control) as well as the best resistance to degradation. The number of living cells in H-PRF gel is greater than 90%. SEM showed that H-PRF gel becomes denser as the heating temperature increases, and rheologic tests also revealed that the heat treatment improved the mechanical properties of H-PRF gels when compared to non-heated control group. Future clinical studies are needed to further support the clinical application of H-PRF gels in tissue regeneration procedures. Conclusions Our results demonstrated that the H-PRF gel obtained at 75 °C for 10 min could produce a uniform, moldable gel with a short time for solidification time, great rheologic behavior and, high percent of live cells in PRF gel. A promising use of the commonly utilized PRF gel was achieved facilitating tissue regeneration and preventing degradation.

show abstract

Colloid determination of fibrin network permeability

Cited by 13 publications

References 0 publications

Tensile strength assay comparing the resistance between two different autologous platelet concentrates (leucocyte-platelet rich fibrin versus advanced-platelet rich fibrin): a pilot study

Tensile strength assay comparing the resistance between two different autologous platelet concentrates (leucocyte-platelet rich fibrin versus advanced-platelet rich fibrin): a pilot study

Fibrin Tissue Adhesives

Exploration of proper heating protocol for injectable horizontal platelet-rich fibrin gel

Contact Info

Product

Resources

About